Loomis Sayles & Co. L P Has $16.66 Million Stake in Xencor Inc (XNCR)

Loomis Sayles & Co. L P grew its holdings in shares of Xencor Inc (NASDAQ:XNCR) by 15.1% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 427,608 shares of the biopharmaceutical company’s stock after acquiring an additional 56,139 shares during the period. Loomis Sayles & Co. L P owned about 0.76% of Xencor worth $16,664,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in XNCR. BlackRock Inc. raised its stake in shares of Xencor by 28.5% during the second quarter. BlackRock Inc. now owns 4,011,155 shares of the biopharmaceutical company’s stock valued at $148,452,000 after acquiring an additional 889,181 shares during the last quarter. FMR LLC increased its position in shares of Xencor by 2.4% during the second quarter. FMR LLC now owns 8,343,753 shares of the biopharmaceutical company’s stock worth $308,802,000 after buying an additional 197,259 shares during the period. Opaleye Management Inc. acquired a new stake in shares of Xencor during the second quarter worth $6,661,000. Northern Trust Corp increased its position in shares of Xencor by 22.3% during the second quarter. Northern Trust Corp now owns 588,155 shares of the biopharmaceutical company’s stock worth $21,768,000 after buying an additional 107,128 shares during the period. Finally, Artal Group S.A. increased its position in shares of Xencor by 25.0% during the third quarter. Artal Group S.A. now owns 500,000 shares of the biopharmaceutical company’s stock worth $19,485,000 after buying an additional 100,000 shares during the period. 82.17% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:XNCR opened at $37.59 on Friday. The firm has a market capitalization of $2.22 billion, a price-to-earnings ratio of -35.80 and a beta of 1.79. Xencor Inc has a 12 month low of $19.89 and a 12 month high of $48.38.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.57. The company had revenue of $29.04 million during the quarter. Equities analysts predict that Xencor Inc will post -1.53 EPS for the current fiscal year.

XNCR has been the subject of several recent analyst reports. BidaskClub cut shares of Xencor from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Zacks Investment Research upgraded shares of Xencor from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Friday, November 9th. BTIG Research initiated coverage on shares of Xencor in a research report on Monday, September 10th. They set a “buy” rating and a $56.00 price objective for the company. Wedbush reiterated an “outperform” rating and set a $42.00 price objective on shares of Xencor in a research report on Monday, October 8th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $40.00 price objective on shares of Xencor in a research report on Tuesday, November 6th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. Xencor has a consensus rating of “Buy” and an average price target of $41.86.

In other Xencor news, major shareholder John S. Stafford III sold 1,000 shares of the firm’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $48.05, for a total value of $48,050.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Paul A. Foster sold 40,000 shares of the firm’s stock in a transaction on Monday, September 17th. The stock was sold at an average price of $46.03, for a total transaction of $1,841,200.00. Following the completion of the sale, the insider now owns 44,952 shares of the company’s stock, valued at $2,069,140.56. The disclosure for this sale can be found here. Company insiders own 4.70% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Loomis Sayles & Co. L P Has $16.66 Million Stake in Xencor Inc (XNCR)” was published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.americanbankingnews.com/2018/12/08/loomis-sayles-co-l-p-has-16-66-million-stake-in-xencor-inc-xncr.html.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.

See Also: Fundamental Analysis

Institutional Ownership by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply